ECMO OutcomesNCT07712835
ECMO Use in Pediatric Oncology and HSCT Patients: A Descriptive and Comparative Analysis
An observational study of ECMO Outcomes and Respiratory Failure (Pediatric Patients), run by Children's Mercy Hospital Kansas City.
Trial summary
This was an observational study, with a descriptive and comparative portion. The descriptive analysis, a large single center experience, examined bleeding complications, infectious rates, and survival outcomes in patients under 18 years old with an underlying oncologic diagnosis and/or hematopoietic stem cell… Read more about this study
- Who is it for?
- Ages 4 weeks to 17 years
- Conditions the study is for
- ECMO Outcomes, Respiratory Failure (Pediatric Patients), Malignancies, Hematologic
- What is being tested?
- Extracorporeal membrane oxygenation (ECMO)
- How many people
- 22 participants
- Where
- No sites listed yet
- Study dates
- Feb 2015to Apr 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 weeks to 17 years
- All sexes
- No healthy volunteers
- Child
Study population: Pediatric patients, under the age of 18, admitted to a tertiary care pediatric intensive care unit for management of respiratory failure warranting mechanical ventilation. Beyond this, only pediatric patients with an underlying oncologic and/or hematopoietic stem cell transplant were included in the study.
Who may be able to join
- Less than 18 years old
- Admitted to the PICU for respiratory failure (2015-2023)
- Underlying oncologic diagnosis and/or hematopoietic stem cell transplant
- Mechanical ventilation
Who cannot join
None listed.
About this study
This was an observational study, with a descriptive and comparative portion. The descriptive analysis, a large single center experience, examined bleeding complications, infectious rates, and survival outcomes in patients under 18 years old with an underlying oncologic diagnosis and/or hematopoietic stem cell transplant on Extracorporeal membrane oxygenation (ECMO). In a small multicenter cohort, the comparative analysis evaluated survival outcomes in this population with respiratory failure in the presence and absence of ECMO. Children's Mercy Kansas City served as the ECMO cohort; Cincinnati Children's Hospital Medical Center served as the matched non-ECMO cohort.
- Conditions
- ECMO Outcomes, Respiratory Failure (Pediatric Patients), Malignancies, Hematologic, Solid Tumor Malignancies, Hematopoetic Stem Cell Transplant
- Being tested
- Extracorporeal membrane oxygenation (ECMO)
- Keywords
- Extracorporeal membrane oxygenation, Respiratory failure, Hematopoietic stem cell transplant, Pediatric Intensive Care Unit, Neoplasms
- Medical subject headings
- Respiratory Insufficiency, Hematologic Neoplasms, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Extracorporeal membrane oxygenation (ECMO)Other
ECMO utilization in patient with malignancy and/or history of hematopoietic stem cell transplant.
| Study group | Role | What they receive |
|---|---|---|
| ECMO Cohort | Eleven patients under 18 years old with an underlying oncologic diagnosis and/or hematopoietic stem cell transplant received Extracorporeal membrane oxygenation (ECMO) as a rescue therapy for respiratory failure. Children's Mercy Hospital served as the ECMO cohort. Receives: Other: Extracorporeal membrane oxygenation (ECMO) | |
| Non-ECMO Cohort | Eleven patients under 18 years old with an underlying oncologic diagnosis and/or hematopoietic stem cell transplant received conventional therapies for management of respiratory failure. Cincinnati Children's Hospital Medical Center served as the non-ECMO cohort. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of survival rates in pediatric patients with an underlying malignancy and/ or hematopoietic stem cell transplant in the presence and absence of ECMO support
Measured: Admission until hospital discharge, average of 46 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2026
- Study startFeb 2015
- Primary completionDec 2024
- Study completionApr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for ECMO OutcomesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Sponsor type
- University, hospital or other
- Collaborators
- Children's Hospital Medical Center, Cincinnati
- Responsible party
- Principal investigator, Michelle Brown, Children's Mercy Hospital Kansas City
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07712835
- Sponsor's protocol ID
- STUDY00001444
- Status last verified
- Jul 2026
- First submitted
- 10 Jul 2026
- Last updated
- 20 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Brown ME, Grassia KL, Miller JO, Holton CR, Hall EM, Lu X, Dandoy CE, Dewan ML, Wagner AF. ECMO Use in Pediatric Oncology and Hematopoietic Stem Cell Transplant Patients: A Descriptive and Comparative Analysis. Pediatr Blood Cancer. 2026 Sep 8:e70647. doi: 10.1002/1545-5017.70647. Online ahead of print.
PubMed 42711927
Study at a glance
From the registry record, last updated by the sponsor on 20 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ECMO Use in Pediatric Oncology and HSCT Patients: A Descriptive and Comparative Analysis
- ClinicalTrials.gov ID
- NCT07712835
- Acronym / sponsor ID
- STUDY00001444
- Conditions
- ECMO Outcomes, Respiratory Failure (Pediatric Patients), Malignancies, Hematologic, Solid Tumor Malignancies, Hematopoetic Stem Cell Transplant
- Keywords
- Extracorporeal membrane oxygenation, Respiratory failure, Hematopoietic stem cell transplant, Pediatric Intensive Care Unit, Neoplasms
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- Children's Mercy Hospital Kansas CityUniversity, hospital or other
- Collaborators
- Children's Hospital Medical Center, Cincinnati
- Study start
- Feb 2015 (actual)
- Primary completion
- Dec 2024 (actual)
- Study completion
- Apr 2025 (actual)
- First posted
- 20 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This was an observational study, with a descriptive and comparative portion. The descriptive analysis, a large single center experience, examined bleeding complications, infectious rates, and survival outcomes in patients under 18 years old with an underlying oncologic diagnosis and/or hematopoietic stem cell transplant on Extracorporeal membrane oxygenation (ECMO). In a small multicenter cohort, the comparative analysis evaluated survival outcomes in this population with respiratory failure in the presence and absence of ECMO. Children's Mercy Kansas City served as the ECMO cohort; Cincinnati Children's Hospital Medical Center served as the matched non-ECMO cohort.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ECMO Cohort | – | Other: Extracorporeal membrane oxygenation (ECMO)Eleven patients under 18 years old with an underlying oncologic diagnosis and/or hematopoietic stem cell transplant received Extracorporeal membrane oxygenation (ECMO) as a rescue therapy for respiratory failure. Children's Mercy Hospital served as the ECMO cohort. |
| Non-ECMO Cohort | – | –Eleven patients under 18 years old with an underlying oncologic diagnosis and/or hematopoietic stem cell transplant received conventional therapies for management of respiratory failure. Cincinnati Children's Hospital Medical Center served as the non-ECMO cohort. |
Who may qualify
- Ages
- 4 weeks to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Pediatric patients, under the age of 18, admitted to a tertiary care pediatric intensive care unit for management of respiratory failure warranting mechanical ventilation. Beyond this, only pediatric patients with an underlying oncologic and/or hematopoietic stem cell transplant were included in the study.
Key inclusion criteria (4 listed)
- Less than 18 years old
- Admitted to the PICU for respiratory failure (2015-2023)
- Underlying oncologic diagnosis and/or hematopoietic stem cell transplant
- Mechanical ventilation
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Extracorporeal membrane oxygenation (ECMO)ECMO utilization in patient with malignancy and/or history of hematopoietic stem cell transplant. | Other | ECMO Cohort |
Primary outcome
Comparison of survival rates in pediatric patients with an underlying malignancy and/ or hematopoietic stem cell transplant in the presence and absence of ECMO support
Time frame: Admission until hospital discharge, average of 46 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jul 2026.
- Derived from this study: PubMed 42711927Brown ME, Grassia KL, Miller JO, Holton CR, Hall EM, Lu X, Dandoy CE, Dewan ML, Wagner AF. ECMO Use in Pediatric Oncology and Hematopoietic Stem Cell Transplant Patients: A Descriptive and Comparative Analysis. Pediatr Blood Cancer. 2026 Sep 8:e70647. doi: 10.1002/1545-5017.70647. Online ahead of print.
- Individual participant dataSharing planned: No
Related trials for ECMO Outcomes
RecruitingObservational study
Prognosis of Veno-Venous Extracorporeal Membrane Oxygenation in Emergency Thoracic Surgery
VV-ECMO, Thoracic Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of ECMO Outcomes and Respiratory Failure (Pediatric Patients), run by Children's Mercy Hospital Kansas City.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison of survival rates in pediatric patients with an underlying malignancy and/ or hematopoietic stem cell transplant in the presence and absence of ECMO support (time frame: Admission until hospital discharge, average of 46 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07712835, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2026; AzTrials last refreshed its copy on 6 Nov 2026.